Your enquiry0Metabolic research
RESEARCH USE ONLYLY3437943, LY-3437943
Retatrutide is a single peptide agonist of GIP, GLP-1 and glucagon receptors, studied across insulin secretion, food intake and energy expenditure. Select your format and quantity for pricing, batch availability and lead time.
Minimum listed format shown. Refer to the selected SKU specifications; final packaging is confirmed with your quotation.
Test method: HPLC. Catalogue specification. Confirm the supplied batch against its COA.
Price, batch and delivery terms confirmed with your quotation.
ABOUT THE MATERIAL
Identity, scientific context and the details that distinguish this entry.
Retatrutide is a single peptide agonist of GIP, GLP-1 and glucagon receptors, studied across insulin secretion, food intake and energy expenditure.[Sources]
Its development code is LY3437943. The glucagon-receptor component adds a metabolic dimension to the GIP/GLP-1 receptor pairing, making receptor balance and integrated whole-body endpoints central to its pharmacology.
Both engage GIPR and GLP-1R. Retatrutide also activates GCGR, allowing study of glucagon-associated energy expenditure alongside incretin-related responses. Each receptor should be measured separately before integrating metabolic endpoints.
A CLOSER LOOK
Read each finding with its study model and material identity.
The LY3437943 discovery study measured activity at GCGR, GIPR and GLP-1R. In obese mice, food-intake and energy-expenditure measurements helped distinguish the contributions of incretin-related and glucagon-related signaling. Early clinical work provided a separate pharmacokinetic and tolerability assessment.
A randomized phase 2 study assessed a defined retatrutide formulation in adults with obesity or overweight and an associated condition. The endpoints included body-weight change over 24 and 48 weeks, gastrointestinal events and heart rate. These clinical measurements complement the receptor studies.
PRODUCT DATA
Product specifications and batch results are confirmed with your quotation and COA.
Review available records or add your document request to the enquiry.
BATCH TESTING
Available reports for this product across its tested packs and batches.
No third-party report is available here for this product. Request batch documents with your enquiry.
Data are provided by a partner laboratory and compiled and reviewed by the issuer named in each report. The reports state that neither party holds CMA/CNAS accreditation. Results cover the submitted samples and named batches; availability for your order is confirmed separately.
BATCH DOCUMENTATION
Add requirements to your enquiry. The team will confirm availability and scope for the offered lot.
Match the offered lot number, identity, test methods and reported results.
Ask for available chromatograms and mass-identity records, including the method and reporting scope.
Confirm handling, transport and storage information for the offered material and packaging.
A document request adds no purchase quantity. Have a batch reference? Open batch records ↗
BEFORE YOU ENQUIRE
Both engage GIPR and GLP-1R. Retatrutide also activates GCGR, allowing study of glucagon-associated energy expenditure alongside incretin-related responses. Each receptor should be measured separately before integrating metabolic endpoints.
Use the specification and available safety or stability information for the offered lot, form and packaging. Request written conditions before ordering; literature alone does not establish a universal temperature, shelf life or reconstitution procedure.
The displayed value is a catalogue specification. Assess the offered lot against its matching COA and method. Chromatographic purity, component content and biological activity are different measurements; confirm which results are available.
Include the exact SKU, quantity in boxes, destination, desired timing and document requirements. State any label or packaging needs. Pricing, availability, lead time and document scope are confirmed in the quotation.
SOURCES
Content updated
Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, O'Farrell LS, Briere DA, Sloop KW, Thomas MK, Pirro V, Wainscott DB, Willard FS, Abernathy M, Morford L, Du Y, Benson C, Gimeno RE, Haupt A, Milicevic Z. 2022, DOI: 10.1016/j.cmet.2022.07.013
Receptor pharmacology and obese mice
Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML, Retatrutide Phase 2 Obesity Trial Investigators. 2023, DOI: 10.1056/nejmoa2301972
Randomized phase 2 trial in adults with obesity
KEGG
Chemical identity reference
Publications describe their own study materials and methods. They are distinct from BatchTide specifications and lot-release records. Materials listed here are for laboratory research only, not for human or veterinary use.
EXPLORE THE CATALOGUE
Explore related entries. Similar research contexts do not establish interchangeability.